Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: Pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials [1]

Leukemia

Volumn 20, Issue 12, 2006, Pages 2169-2171

  Weiss, J R ^a   Kopecky, K J ^b   Godwin, J ^c   Anderson, J ^d   Willman, C L ^e   Moysich, K B ^a   Slovak, M L ^f   Hoque, A ^g   Ambrosone, C B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d Katmai Oncology Group   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GENOMIC DNA; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GENE FUNCTION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; SURVIVAL RATE; SURVIVAL TIME;

EID: 33751247931     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404421     Document Type: Letter

References (8)

1. Joel SP, Rohatiner A. Pharmacology of antileukemic drugs. In: Henderson ES, Lister TA, Greaves MF (eds). Leukemia, Saunders: Philadelphia, PA, 2002, pp 394-440.
2. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999; 31: 273-300.
3. Ambrosone CB, Tian C, Ahn J, Kropp S, Helmbold I, von Fournier D et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: A case-series study. Breast Cancer Res 2006; 8: R40.
4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
5. Autrup JL, Hokland P, Pedersen L, Autrup H. Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur J Pharmacol 2002; 438: 15-18.
6. Voso MT, D'Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703-2707.
7. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: Increased early death after chemotherapy. Leukemia 2002; 16: 203-208.
8. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279-1287.